Drugs that lack single-agent activity: are they worth pursuing in combination?

被引：26

作者：

Gyawali, Bishal ^{[1
]}

Prasad, Vinay ^{[2
,3
,4
]}

机构：

[1] Nobel Hosp, Dept Haematooncol, Kathmandu 21034, Nepal

[2] OSHU, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97239 USA

[3] OSHU, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA

[4] Ctr Eth Hlth Care, 3181 South West Sam Jackson Pk Rd, Portland, OR 97239 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 04期

关键词：

METASTATIC BREAST-CANCER; MULTIPLE-MYELOMA; TRIAL; MULTICENTER; DOXORUBICIN; BORTEZOMIB;

D O I：

10.1038/nrclinonc.2017.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.

引用

页码：1 / 2

页数：2

共 50 条

[41] TREATMENT OF COMBINATION CHEMOTHERAPY-RESISTANT HODGKIN DISEASE WITH SINGLE-AGENT VINBLASTINE
WARREN, RD
BENDER, RA
NORTON, L
YOUNG, RC
AMERICAN JOURNAL OF HEMATOLOGY, 1978, 4 (01) : 47 - 55
[42] Single-agent/combination therapy of human immunodeficiency virus-related wasting
Wanke, C
SEMINARS IN ONCOLOGY, 1998, 25 (02) : 98 - 103
[43] Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
Weber, Michael A.
Julius, Stevo
Kjeldsen, Sverre E.
Jia, Yan
Brunner, Hans R.
Zappe, Dion H.
Hua, Tsushung A.
McInnes, Gordon T.
Schork, Anthony
Mancia, Giuseppe
Zanchetti, Alberto
JOURNAL OF HYPERTENSION, 2012, 30 (11) : 2213 - 2222
[44] Combination versus sequential single-agent therapy for the treatment of metastatic breast cancer
Modi, S
Seidman, A
EJC SUPPLEMENTS, 2005, 3 (05): : 3 - 8
[45] Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens
Richardson, Michael
Chase, Dana M.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2024, 36 (01) : 1 - 8
[46] Single-agent vs combination therapy in advanced breast cancer: Potential roles of capecitabine
Hudis, CA
ONCOLOGY-NEW YORK, 2002, 16 (10): : 13 - 16
[47] Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone
Dimopoulos, MA
Tsatalas, C
Zomas, A
Hamilos, G
Panayiotidis, P
Margaritis, D
Matsouka, C
Economopoulos, T
Anagnostopoulos, N
SEMINARS IN ONCOLOGY, 2003, 30 (02) : 265 - 269
[48] Treatment of unresectable or metastatic gallbladder cancer with single-agent gemcitabine or in combination with cisplatin.
Gallardo, J
Rubio, B
Barajas, O
Villanueva, L
Fodor, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 360S - 360S
[49] Treatment of indolent nonHodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone
Armitage, JO
Tobinai, K
Hoelzer, D
Rummel, MJ
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (04) : 311 - 321
[50] Dovitinib as a single-agent or in combination with other small molecule inhibitors for mutant BRAF melanomas
Langdon, Casey G.
Held, Matthew A.
Koo, Andrew B.
Klein, Michael
Liu, Zongzhi
Platt, James T.
Stern, David F.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

← 1 2 3 4 5 →